APRI Apricus Biosciences

Seelos Therapeutics Added to Russell Microcap® Index

Seelos Therapeutics Added to Russell Microcap® Index

NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has been added to the Russell Microcap® Index, effective as of the close of the U.S. markets Friday, June 28, 2019.

The Russell Microcap® Index is comprised of the 1,000 smallest market capitalization companies in the Russell 2000® Index plus approximately 500 additional companies.

Additional information on the Russell Microcap® Index and Reconstitution can be found on:

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York. For more information, please visit our website: , the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano

Head of Corporate Communications

Seelos Therapeutics, Inc. (NASDAQ: SEEL)

300 Park Ave., 12th Fl

New York, NY 10022

(646) 293-2136





EN
01/07/2019

Underlying

APRIApricus Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apricus Biosciences

 PRESS RELEASE
Free
APRI Apricus Bioscie...

Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I...

Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002 NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to provide updates regarding data from the Phase I study of SLS-002 on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time. Seelos will also provide an overview of the design for Seelos’ next study of ...

June 15, 2020 1 EN
 PRESS RELEASE
Free
APRI Apricus Bioscie...

Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-0...

Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease Gene Therapy Program to Target the Regulation of the SNCA Gene of Alpha-Synuclein NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the initiation of a preclinical study of SLS-004 in Parkinson’s disease (PD) through an all-in-one lentiviral vector targeting the synuclein alpha (SNCA) gene. Seelos is con...

May 28, 2020 1 EN
 PRESS RELEASE
Free
APRI Apricus Bioscie...

Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unm...

Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to discuss the unmet medical needs in suicide and depression on Tuesday, May 26, 2020 at 1:00 p.m. Eastern Time. The call will feature a discussion with Distinguished University Health Profes...

May 19, 2020 1 EN
 PRESS RELEASE
Free
APRI Apricus Bioscie...

Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual...

Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference, June 15-16, 2020. Raj Mehra, Ph.D., Chairman and CEO, will host meetings via conference calls. For additional information about the Benchmark Company Healt...

May 18, 2020 1 EN
 PRESS RELEASE
Free
APRI Apricus Bioscie...

Seelos Therapeutics Announces Appointment of Judith Dunn to the Board ...

Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Judith Dunn, Ph.D. to its Board of Directors. Dr. Dunn has had an extensive career in the pharmaceutical and biotechnology industries having served in various roles at F. Hoffman-La Roche AG from March 2010 through January 2018, including Vice Presiden...

May 15, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch